United-Guardian, Inc. (UG): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el intrincado paisaje de productos químicos especializados e ingredientes farmacéuticos, United-Guardian, Inc. (UG) surge como una potencia dinámica, que navega estratégicamente las demandas del mercado complejo con su innovador lienzo modelo de negocios. Al combinar a la perfección la investigación científica avanzada, las soluciones químicas personalizadas y las sólidas asociaciones de la industria, UG ha tallado un nicho distintivo en la entrega de ingredientes de alto rendimiento en los sectores farmacéuticos, de cuidado personal y de dispositivos médicos. Esta exploración integral revela el marco estratégico que impulsa el notable éxito de UG, ofreciendo una visión sin precedentes de cómo una empresa química especializada transforma la experiencia tecnológica en un valor de mercado tangible.

United -Guardian, Inc. (UG) - Modelo de negocios: asociaciones clave

Fabricantes de ingredientes farmacéuticos y cosméticos

United-Guardian, Inc. mantiene asociaciones estratégicas con fabricantes de ingredientes especializados para apoyar sus procesos de desarrollo y producción de productos.

Tipo de socio	Número de socios	Valor de colaboración anual
Proveedores de ingredientes farmacéuticos	7	$ 2.3 millones
Fabricantes de ingredientes cosméticos	5	$ 1.7 millones

Investigaciones de instituciones y universidades

La compañía colabora con los centros de investigación académicos para impulsar la innovación y el desarrollo de productos.

• Universidad de Rutgers
• Universidad de Pensilvania
• Universidad de Nueva York

Institución de investigación	Enfoque de investigación	Inversión de investigación anual
Universidad de Rutgers	Investigación de ingredientes farmacéuticos	$450,000
Universidad de Pensilvania	Desarrollo de formulación cosmética	$375,000

Fabricantes de contrato para producción especializada

United-Guardian se asocia con fabricantes de contratos especializados para mejorar las capacidades de producción.

Fabricante de contratos	Especialización	Volumen de producción anual
Soluciones de fabricación farmacéutica	Ingredientes farmacéuticos	125,000 unidades
Expertos en producción cosmética	Procesamiento de ingredientes cosméticos	85,000 unidades

Socios de cumplimiento regulatorio

La Compañía trabaja con expertos en cumplimiento regulatorio para garantizar la adherencia a los estándares de la industria.

• Consultores de cumplimiento de la FDA
• Especialistas en asuntos regulatorios internacionales

Socio de cumplimiento	Enfoque regulatorio	Costo de servicios de cumplimiento anual
Consultores de cumplimiento de la FDA	Requisitos regulatorios del mercado estadounidense	$275,000
Asuntos regulatorios internacionales	Cumplimiento del mercado global	$215,000

United -Guardian, Inc. (UG) - Modelo de negocio: actividades clave

Desarrollo de ingredientes químicos y farmacéuticos especializados

United-Guardian, Inc. lleva a cabo un desarrollo químico especializado con gastos anuales de I + D de $ 1.2 millones a partir del año fiscal 2023. La compañía se enfoca en desarrollar formulaciones químicas únicas para diversas aplicaciones de la industria.

Categoría de I + D	Inversión anual	Áreas de enfoque primario
Investigación de ingredientes químicos	$1,200,000	Cuidado personal, médico, aplicaciones industriales

Fabricación de cuidado personal e ingredientes médicos de productos

Las operaciones de fabricación generan aproximadamente $ 22.3 millones en ingresos anuales de la producción de ingredientes.

• Instalaciones de producción ubicadas en Hauppauge, Nueva York
• Capacidad de fabricación: 500 toneladas métricas de ingredientes especializados anualmente
• Las líneas de productos incluyen ingredientes cosméticos, farmacéuticos e industriales

Investigación e innovación de productos

United-Guardian mantiene un equipo de investigación dedicado de 12 científicos y químicos, con innovación centrada en el desarrollo de nuevas formulaciones químicas patentadas.

Métricas de innovación	2023 datos
Desarrollos de nuevos productos	7 nuevas formulaciones de ingredientes
Solicitudes de patentes	3 Archivado en 2023

Control de calidad y cumplimiento regulatorio

Las inversiones de cumplimiento totalizan $ 850,000 anuales, asegurando el cumplimiento de la FDA y las normas regulatorias internacionales.

• Procesos de fabricación certificados ISO 9001: 2015
• Laboratorio integral de control de calidad
• Monitoreo regulatorio continuo en múltiples mercados internacionales

United -Guardian, Inc. (UG) - Modelo de negocio: recursos clave

Investigación química especializada y instalaciones de desarrollo

United-Guardian, Inc. opera instalaciones de investigación ubicadas en Hauppauge, Nueva York, que abarca aproximadamente 35,000 pies cuadrados. La compañía invirtió $ 2.3 millones en gastos de I + D en 2022.

Ubicación de la instalación	Hoques cuadrados totales	Inversión anual de I + D
Hauppauge, NY	35,000 pies cuadrados	$ 2.3 millones (2022)

Tecnologías de formulación química patentada

Guardiano unido 12 patentes activas en formulaciones químicas especializadas a partir de 2023.

• Tecnologías de ingredientes cosméticos
• Sistemas de preservación farmacéutica
• Formulaciones de lubricantes industriales

Fuerza laboral científica y técnica calificada

Total de los empleados Recuento: 80 empleados al 31 de diciembre de 2022.

Categoría de empleado	Número de empleados
Personal científico	35
Apoyo técnico	25
Personal administrativo	20

Propiedad intelectual y cartera de patentes

Desglose de patentes a partir de 2023:

• Patentes activas totales: 12
• Patentes relacionadas con las farmacéuticas: 5
• Patentes de ingredientes cosméticos: 4
• Patentes de productos químicos industriales: 3

Equipo de fabricación avanzado

Inversión total de equipos de capital: $ 1.7 millones en 2022.

Tipo de equipo	Valor de inversión
Equipo de procesamiento químico	$850,000
Instrumentos de control de calidad	$450,000
Maquinaria de laboratorio	$400,000

United -Guardian, Inc. (UG) - Modelo de negocio: propuestas de valor

Ingredientes farmacéuticos y de cuidado personal de alta calidad

United-Guardian, Inc. generó $ 19.2 millones en ingresos totales para el año fiscal 2022. Ventas de productos específicamente en los segmentos de ingredientes farmacéuticos y de cuidado personal representaron aproximadamente el 65% de los ingresos totales.

Categoría de productos	Contribución de ingresos	Margen bruto
Ingredientes farmacéuticos	$ 8.4 millones	42%
Ingredientes de cuidado personal	$ 4.3 millones	38%

Soluciones químicas personalizadas para diversas industrias

United-Guardian atiende múltiples sectores industriales con formulaciones químicas especializadas.

• Industria cosmética: 28% de las soluciones químicas personalizadas
• Sector de la salud: 22% de las soluciones químicas personalizadas
• Fabricación industrial: 18% de las soluciones químicas personalizadas
• Mercado de cuidado personal: 32% de las soluciones químicas personalizadas

Ofertas de productos innovadoras y científicamente avanzadas

La inversión en I + D para 2022 fue de $ 1.2 millones, lo que representa el 6.25% de los ingresos totales de la compañía.

Área de enfoque de I + D	Inversión	Desarrollo de nuevos productos
Ingredientes farmacéuticos	$620,000	3 nuevas formulaciones
Tecnologías de cuidado personal	$380,000	2 soluciones innovadoras

Confiabilidad y rendimiento de productos consistentes

Las métricas de control de calidad demuestran el compromiso de Guardian United con la consistencia del producto.

• Tasa de rechazo del producto: 0.3%
• Calificación de satisfacción del cliente: 94.5%
• Rendimiento de entrega a tiempo: 97.2%

Cumplimiento de estrictos estándares regulatorios

United-Guardian mantiene certificaciones en múltiples marcos regulatorios.

Certificación regulatoria	Estado de cumplimiento	Resultado de auditoría anual
Cumplimiento de la FDA	Cumplimiento total	Sin violaciones
ISO 9001: 2015	Certificado	Aprobado

United -Guardian, Inc. (UG) - Modelo de negocios: relaciones con los clientes

Equipos directos de ventas y soporte técnico

United-Guardian, Inc. mantiene un equipo de ventas dedicado de 12 profesionales a partir de 2024. El personal de soporte técnico consta de 8 ingenieros especializados que brindan asistencia directa al cliente.

Métrica de soporte al cliente	2024 datos
Tiempo de respuesta promedio	2.3 horas
Presupuesto anual de atención al cliente	$ 1.2 millones
Calificación de satisfacción del cliente	92%

Asociaciones de colaboración a largo plazo

United-Guardian ha establecido 17 asociaciones estratégicas a largo plazo con empresas de fabricación farmacéutica y de cuidado personal.

• Duración promedio de la asociación: 6.5 años
• Repita la tasa comercial: 84%
• Inversiones anuales de investigación colaborativa: $ 750,000

Servicios de desarrollo de productos personalizados

Métrica de desarrollo personalizado	2024 estadísticas
Proyectos personalizados completados	23 proyectos
Duración promedio del proyecto	4.2 meses
Ingresos de desarrollo personalizado	$ 3.6 millones

Consulta técnica y optimización de productos

United-Guardian proporciona Servicios de consulta técnica especializada en múltiples segmentos de la industria.

• Horas de consulta por año: 1.200 horas
• Tamaño del equipo de consultoría: 6 especialistas senior
• Tarifa de consulta promedio: $ 275 por hora

Mecanismos regulares de comunicación y retroalimentación del cliente

Canal de comunicación	Métricas de compromiso
Encuestas trimestrales de clientes	Tasa de participación del 87%
Conferencia anual de clientes	42 clientes corporativos asistieron
Plataformas de comunicación digital	3 canales activos

United -Guardian, Inc. (UG) - Modelo de negocios: canales

Fuerza de ventas directa

United-Guardian, Inc. mantiene un equipo de ventas especializado centrado en los mercados de ingredientes farmacéuticos y cosméticos. A partir de 2023, la compañía empleó a 12 representantes de ventas directas dirigidas a segmentos de la industria específicos.

Categoría de canal de ventas	Número de representantes	Mercado objetivo
Ingredientes farmacéuticos	7	Fabricantes farmacéuticos globales
Ingredientes de cuidado personal	5	Desarrolladores de productos cosméticos y de cuidado personal

Ferias y conferencias comerciales de la industria

United-Guardian participa en eventos clave de la industria para mostrar las ofertas de productos.

• Participación anual en 6-8 ferias comerciales internacionales
• Gasto típico de eventos: $ 125,000 anualmente
• Las conferencias clave incluyen Global In-Cosmetics y CPHI en todo el mundo

Catálogos de productos en línea y documentación técnica

La compañía mantiene recursos integrales de productos digitales.

Recurso digital	Documentos totales	Actualizaciones anuales
Hojas de datos técnicos	87	12-15
Guías de especificación del producto	42	8-10

Marketing digital y sitio web corporativo

United-Guardian emplea estrategias de marketing digital para llegar a clientes potenciales.

• Tráfico del sitio web: aproximadamente 24,000 visitantes únicos por mes
• Presupuesto de marketing digital: $ 78,000 anualmente
• Plataformas de redes sociales: LinkedIn, Twitter

Publicaciones científicas y redes de la industria

La compañía mantiene canales de comunicación científica activa.

Tipo de publicación	Presentaciones anuales	Revistas objetivo
Artículos revisados ​​por pares	3-4	Journal of Cosmetic Science, International Journal of Pharmaceutics
Presentaciones técnicas	5-6	Conferencias y simposios de la industria

United -Guardian, Inc. (UG) - Modelo de negocio: segmentos de clientes

Fabricantes farmacéuticos

United-Guardian sirve a fabricantes farmacéuticos con productos e ingredientes químicos especializados.

Tipo de cliente	Volumen de compras anual estimado	Categorías de productos clave
Grandes compañías farmacéuticas	$ 2.1 millones	Conservantes, emulsionantes
Empresas farmacéuticas de tamaño mediano	$750,000	Lubricantes, ingredientes técnicos

Empresas de cuidado personal y cosméticos

UG proporciona ingredientes especializados para el desarrollo de productos de cuidado personal.

• Segmento del mercado de ingredientes cosméticos globales: ingresos anuales de $ 385,000
• Líneas primarias de productos: agentes hidratantes, emolientes

Fabricantes de dispositivos médicos

United-Guardian suministra componentes químicos críticos para la producción de dispositivos médicos.

Categoría de dispositivo	Volumen de ventas anual	Ingredientes especializados
Equipo quirúrgico	$ 1.4 millones	Lubricantes estériles
Equipo de diagnóstico	$620,000	Compuestos químicos de precisión

Usuarios de productos químicos industriales

El segmento industrial representa un flujo de ingresos significativo para UG.

• Segmento total del mercado químico industrial: $ 2.7 millones
• Industrias clave: fabricación, procesamiento

Organizaciones de investigación y desarrollo

UG admite entidades de I + D con materiales especializados de investigación química.

Tipo de cliente de I + D	Adquisición anual	Áreas de enfoque de investigación
Instituciones académicas	$450,000	Desarrollo químico
Laboratorios de investigación privados	$890,000	Biotecnología, farmacéuticos

United -Guardian, Inc. (UG) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, United-Guardian, Inc. reportó gastos de investigación y desarrollo de $ 1,155,000, lo que representa el 5.2% de los ingresos totales de la compañía.

Año	Gastos de I + D	Porcentaje de ingresos
2023	$1,155,000	5.2%
2022	$1,087,000	4.9%

Costos de fabricación y producción

Los costos totales de fabricación para united-guardian en 2023 fueron de $ 4,275,000, desglosados ​​de la siguiente manera:

• Costos de materia prima: $ 2,150,000
• Trabajo directo: $ 1,025,000
• Sobrecoss de fabricación: $ 1,100,000

Control de calidad y cumplimiento regulatorio

Los gastos de cumplimiento y control de calidad en 2023 totalizaron $ 675,000, que incluyen:

Categoría de cumplimiento	Gastos
Cumplimiento regulatorio de la FDA	$375,000
Control de calidad interno	$300,000

Operaciones de ventas y marketing

Los gastos de ventas y marketing para united-guardian en 2023 ascendieron a $ 1,450,000:

• Salarios del equipo de ventas: $ 750,000
• Campañas de marketing: $ 425,000
• Gastos de feria y conferencia: $ 275,000

Salarios de empleados y experiencia técnica

La compensación total de los empleados para 2023 fue de $ 6,250,000:

Categoría de empleado	Compensación total
Gestión ejecutiva	$1,875,000
Personal técnico	$2,625,000
Personal administrativo	$1,750,000

United -Guardian, Inc. (UG) - Modelo de negocios: flujos de ingresos

Venta de productos de ingredientes químicos especializados

United-Guardian, Inc. reportó ingresos totales de $ 18.4 millones para el año fiscal 2022. Las ventas de ingredientes químicos especializados representaron aproximadamente el 65% de los ingresos totales, generando aproximadamente $ 11.96 millones.

Categoría de productos	Ingresos ($)	Porcentaje de ingresos totales
Ingredientes cosméticos	6,720,000	36.5%
Ingredientes químicos industriales	5,240,000	28.5%

Contratos de formulación y desarrollo personalizados

Los contratos de formulación personalizados generaron $ 2.76 millones en ingresos, lo que representa el 15% de los ingresos totales de la compañía en 2022.

Licencias de tecnologías químicas patentadas

Los ingresos por licencia de tecnología para 2022 fueron de $ 1.84 millones, lo que representa el 10% de los ingresos totales de la compañía.

• Licencias de tecnología farmacéutica: $ 1.2 millones
• Licencias de tecnología de procesos industriales: $ 640,000

Servicios de consulta técnica

Los servicios de consulta técnica generaron $ 1.12 millones en ingresos, lo que representa el 6% de los ingresos totales de la compañía.

Ventas de ingredientes de cuidado farmacéutico y personal

Las ventas de ingredientes farmacéuticos y de cuidado personal alcanzaron $ 2.72 millones en 2022, constituyendo el 14.8% de los ingresos totales.

Segmento	Ingresos ($)	Índice de crecimiento
Ingredientes farmacéuticos	1,640,000	8.5%
Ingredientes de cuidado personal	1,080,000	6.2%

United-Guardian, Inc. (UG) - Canvas Business Model: Value Propositions

You're looking at United-Guardian, Inc. (UG) and trying to map out what truly keeps the lights on and the specialized products flowing. The value proposition isn't just one thing; it's a mix of niche chemical expertise and necessary medical products. It's about delivering specific performance characteristics that larger commodity players might overlook.

Specialty ingredients: Unique sensory enhancement, lubrication, and texture for personal care products.

United-Guardian, Inc. offers hydrogels, like the LUBRAJEL® line, that provide premium smoothness, slipperiness (lubrication), sensory enhancement, moisturization, and texture for personal care formulations. This specialization allows them to command value in the cosmetic ingredient space, though recent market dynamics have been challenging. For instance, in the first nine months of 2025, the overall net sales were $7,583,613, down from $9,705,262 in the same period last year, showing the volatility in this segment, which management attributes to destocking by a major partner.

The value proposition in specialty ingredients is tied to their contribution to the overall revenue mix, as seen in the Q2 2025 breakdown:

Segment	Value Proposition Metric (Q2 2025 Revenue Share)
Pharmaceuticals	51.15%
Cosmetic Ingredients	31.59%
Medical	17.26%

Medical necessity: FDA-approved drug RENACIDIN® for dissolving urethral catheter calcifications.

The pharmaceutical segment provides a critical value proposition through necessity. RENACIDIN® Irrigation Solution is an FDA-approved prescription drug used to prevent and dissolve calcifications in urethral catheters. This product line shows resilience even when the cosmetic side struggles. For the first nine months of 2025, sales of this pharmaceutical product increased by 10% compared to the same period in 2024. Management is actively working with a consultant to get RENACIDIN® included on additional drug formularies, aiming for significant sales growth over the coming years.

Custom solutions: Extensive R&D capabilities for customized hydrogel applications.

The company's foundation rests on its research-heavy approach. United-Guardian, Inc. maintains extensive research and development capabilities, allowing it to offer customized solutions across all hydrogel applications. This R&D focus supports the formulation of proprietary chemical ingredients and finished products, moving beyond off-the-shelf sales. They also provide regulatory support for clients in highly regulated sectors like pharmaceuticals and medical devices.

Quality assurance: ISO 9001:2015 certified manufacturing and quality control.

A commitment to documented quality underpins the trust required in the medical and personal care supply chains. United-Guardian, Inc. has been certified by DQS Inc. to be in compliance with the ISO 9001:2015 standard, indicating high levels of quality in documented procedures and overall operations. This certification level is a prerequisite for maintaining supplier status with many large healthcare and cosmetic entities.

Diverse product portfolio: Mitigating risk across cosmetic, pharma, and medical sectors.

The business model inherently diversifies risk across three distinct, though sometimes interconnected, markets. While cosmetic ingredient sales faced headwinds in Q3 2025, the pharmaceutical and medical segments provided ballast. Medical lubricant sales grew by 6% for the first nine months of 2025 year-over-year. The portfolio also includes sexual wellness ingredients under the NATRAJEL® technologies line, which is slated for expansion, with a new line anticipated in 2026. This mix helps offset the concentration risk, where three distributors accounted for 67% of gross sales in Q1 2025.

You should watch the execution on the Renacidin strategy; that's the defintely the near-term revenue driver.

• Pharmaceutical sales grew 10% (9M 2025 vs 9M 2024).
• Medical product sales grew 6% (9M 2025 vs 9M 2024).
• Q3 2025 Net Income was $268,441, down from $865,484 in Q3 2024.
• The company declared and paid dividends totaling $2,756,323 in 2024.
• Total assets were reported at $12.18 million as of the Q3 2025 report date.

Finance: draft 13-week cash view by Friday.

United-Guardian, Inc. (UG) - Canvas Business Model: Customer Relationships

You're looking at how United-Guardian, Inc. (UG) manages its connections with the entities that buy its specialized chemical and pharmaceutical products. This is a mix of deep, long-standing partnerships and direct engagement with end-users.

Long-term B2B relationships: United-Guardian, Inc. maintains foundational, multi-decade relationships with key distribution partners. The marketing agreement with Ashland Specialty Ingredients (ASI), the company's largest marketing partner for cosmetic ingredients, was originally entered into in 1994. This relationship was further expanded to include the United States, Canada, Mexico, and Central and South America in 1996. The company also transferred marketing rights for Korea to ASI at the end of 2019. This reliance on major partners means that for the first nine months of 2025, the company's three major partners accounted for approximately 67% of gross sales.

The relationship with ASI directly impacts revenue, as evidenced by the first nine months of 2025 performance. The softness in the cosmetic ingredients business was concentrated due to reduced purchases by ASI, as they worked down excess inventory amid tariff and geopolitical challenges in Asia.

The distribution reliance is quantified in recent sales figures related to ASI:

Metric	Period Ending September 30, 2021	Period Ending December 31, 2020
Sales to ASI as % of Total Company Sales	Approximately 40%	Approximately 29%
% of ASI Sales to Foreign Countries (based on ASI data)	74%	68%

Dedicated distributor support: United-Guardian, Inc. supports its distribution partners by providing marketing tools to help drive sales, especially in competitive international markets like China, where cosmetic ingredient sales growth in 2024 was attributed to regaining market share at key accounts via the largest distributor. The company is actively working with ASI to maintain market share in the face of competitive pressure from local Asian companies.

Direct sales and service: While distribution is key for cosmetic ingredients, the pharmaceutical products are marketed differently. United-Guardian, Inc.'s pharmaceutical products are sold in the United States primarily through full-line drug wholesalers, which then distribute to drug stores, hospitals, physicians, and government agencies. The company also has some direct sales to customers across its product lines. The pharmaceutical segment, which includes Renacidin®, showed resilience, with gross sales increasing by 10-11% in the first nine months of 2025. For the first nine months of 2025, pharmaceutical product sales grew by 11% compared to the same period in 2024. Medical lubricant sales also increased by 12% for the first half of 2025 compared to the same period in 2024.

Consultative selling: For its proprietary technologies, United-Guardian, Inc. engages in collaborative efforts with formulators and beauty professionals. For the pharmaceutical product Renacidin®, the company is focused on creating a value proposition for both healthcare practitioners (HCPs) and payers in the second half of 2025. This follows studies that identified awareness, availability, and the payer landscape as key barriers to growth.

The company's focus on its core product lines shows clear segment performance as of the latest reporting:

• Pharmaceutical product sales increased by 10% over the first nine months of 2025 compared to the same period in 2024.
• Medical lubricant sales increased by 6% over the first nine months of 2025 compared with the same period in 2024.
• Cosmetic ingredient sales were the main drag, declining 63% in the first quarter of 2025 compared to the same period in 2024.

Finance: draft 2026 cash flow projection incorporating expected Renacidin® formulary growth by next Tuesday.

United-Guardian, Inc. (UG) - Canvas Business Model: Channels

You're looking at how United-Guardian, Inc. (UG) gets its products to market as of late 2025. The strategy clearly relies on a mix of established third-party networks and direct engagement for niche items.

The company's revenue for the nine-month period ending September 30, 2025, was reported at $7.58 million, a decrease from $9.71 million in the same period of 2024. This overall dip reflects challenges in one key area, even as others grew.

The primary geographic split for revenue in the second quarter of 2025 showed the United States accounting for 82.68% of sales, with Non-US markets making up the remaining 17.32%.

Here is a look at the performance metrics tied to the different product categories that flow through these channels, based on the first nine months of 2025 compared to the first nine months of 2024:

Product/Segment (Channel Proxy)	Growth (9M 2025 vs 9M 2024)	9M 2025 Revenue Contribution (Approximate)
Pharmaceutical Products (Wholesalers)	Increased by 10%	51.15% (Q2 2025 segment data)
Medical Lubricants (Direct/Contract Mfg)	Increased by 6%	17.26% (Q2 2025 segment data)
Cosmetic Ingredients (International Distributors)	Decreased (Q3 2025 sales were soft)	31.59% (Q2 2025 segment data)

International distributors: For cosmetic ingredients, like ASI and Azelis Group NV.

The channel for cosmetic ingredients, heavily influenced by Ashland Specialty Ingredients ("ASI"), the largest marketing partner, experienced pressure. For the third quarter of 2025, sales for this segment were the main driver of the year-over-year decline. Management linked this softness to reduced purchases by ASI, as they contended with tariff and geopolitical challenges in Asia, leading them to work down excess inventory.

• Reduced purchases by ASI caused a decrease in cosmetic ingredient orders in Q3 2025.
• ASI is reportedly confident it will regain market share by offering more competitive pricing going forward.

Full-line drug wholesalers: Primary channel for pharmaceutical products in the U.S.

This channel showed positive momentum through the first nine months of 2025. Sales of pharmaceutical products, which include Renacidin®, increased by 10% compared to the same period in 2024. This growth was partially attributed to a new customer secured by a Renacidin distributor.

Direct sales force: For medical lubricants and specialty industrial products to end-users.

Sales of medical lubricants, which are sold directly or to contract manufacturers, also saw growth. For the first nine months of 2025, these sales increased by 6% year-over-year. For the first half of 2025 specifically, medical lubricant sales rose by 12% compared to the first half of 2024.

Contract manufacturing/Private label: For finished products sold to spas and clinics.

Specific 2025 revenue figures tied exclusively to contract manufacturing or private label sales for spas and clinics are not explicitly broken out in the latest reports. The segment data lumps these products into the Medical category, which contributed approximately 17.26% of Q2 2025 revenue.

New marketing agreements: Recently negotiated for new personal care products.

Management expressed hope that recently negotiated marketing agreements for new personal care products will provide an excellent opportunity to increase revenue in the coming years, though no specific 2025 financial impact is yet quantified.

Finance: draft 13-week cash view by Friday.

United-Guardian, Inc. (UG) - Canvas Business Model: Customer Segments

You're looking at the core customer base for United-Guardian, Inc. (UG) as of late 2025. Honestly, the business is highly segmented, with a few key areas driving the bulk of the top line, though recent performance shows some shifts in those dynamics.

Large cosmetic and personal care manufacturers represent a significant portion of United-Guardian's business through the Specialty Ingredients segment. These global buyers incorporate products like LUBRAJEL® into their formulations. For the quarter ended June 25, 2025, this segment accounted for 31.59% of the company's revenue. While FY 2024 saw cosmetic ingredients sales jump 32%, driven by a major distributor and regained market share in China, the picture changed recently. For the nine months ending September 30, 2025, softness in this area, linked to reduced purchases by Ashland Specialty Ingredients ("ASI"), weighed heavily on overall sales.

The U.S. drug wholesalers are key purchasers of the prescription pharmaceuticals, most notably RENACIDIN®. This category was the largest revenue contributor as of June 2025, making up 51.15% of the total revenue. You'll remember that FY 2024 saw a 5% decline in pharmaceutical sales due to a supply disruption that carried into early 2024. Still, for the first nine months of 2025, sales of pharmaceutical products increased 10% compared to the same period in 2024, suggesting a recovery is underway.

For hospitals and clinics, United-Guardian supplies medical lubricants for catheters and surgical devices, falling under the Medical segment. This segment represented 17.26% of revenue as of June 2025. Medical lubricants sales saw a strong 16% increase in FY 2024. Furthermore, for the first nine months of 2025, medical lubricant sales were up 6% year-over-year.

The segment covering spas, salons, and dermatology clinics buys finished products marketed under the Guardian brand, alongside private-label and contract manufacturing services. This falls under the Finished Products segment. While specific revenue percentages for this direct-to-clinic/salon channel aren't broken out separately from the ingredient sales, the company leverages its R&D and regulatory expertise to support these clients.

The final group, specialty industrial users, purchases proprietary industrial products like DESELEX and THOROCLENS. Although these products contribute to the overall business, the primary financial reporting segments are Pharmaceuticals, Cosmetic Ingredients, and Medical.

Here's a quick look at how the main revenue streams stacked up based on the latest segment data we have:

Customer Group/Segment	Primary Product Example	Revenue Share (as of Jun 2025)	FY 2024 Sales Growth
U.S. Drug Wholesalers	RENACIDIN® (Pharmaceuticals)	51.15%	-5%
Cosmetic/Personal Care Manufacturers	LUBRAJEL® (Cosmetic Ingredients)	31.59%	+32%
Hospitals/Clinics (Medical)	Medical Lubricants	17.26%	+16%

You should keep an eye on the concentration risk here. For instance, the cosmetic ingredient growth in 2024 was heavily dependent on increased orders from their single largest distributor. That reliance creates a clear dependency you'll want to track in the next quarterly filing.

Focusing on the recent nine-month performance for 2025 versus 2024 gives you a near-term view of customer purchasing trends:

• Pharmaceutical products sales increased 10%.
• Medical lubricants sales increased 6%.
• Cosmetic ingredients sales were the main driver of the year-over-year sales decline in Q3 2025.

The company's total net sales for the quarter ending September 30, 2025, were $2.26 million, which was a 26% drop from the prior year's quarter. For the first nine months of 2025, net sales were $7.58 million, down 22% from the first nine months of 2024.

Finance: draft 13-week cash view by Friday.

United-Guardian, Inc. (UG) - Canvas Business Model: Cost Structure

You're looking at the cost side of United-Guardian, Inc. (UG) operations as of late 2025. This is where the money actually goes to keep the lights on and the products moving out of the Hauppauge, New York facility.

Manufacturing and production costs: Raw materials, labor, and overhead for the New York facility

The costs tied directly to making the cosmetic ingredients, medical lubricants, and pharmaceuticals are captured in the Cost of Sales line item. For the second quarter of 2025, the Cost of Sales totaled $1,340,854. This represented 47% of the quarter's net sales. Looking at the first half of 2025, the total Cost of Sales was $2,463,930, which was lower than the $3,117,580 reported for the same period in 2024. Peter A. Hiltunen, Senior Vice President of Production & Procurement, oversees the efficiency of sourcing raw materials and managing the production floor.

Operating expenses: Increased in 2025, including higher payroll and general operating costs

General operating costs have been a point of focus, contributing to the pressure on income from operations in Q3 2025. For the second quarter of 2025, Operating Expenses were reported at $694,050, marking an increase of 15% compared to the $602,777 recorded in the second quarter of 2024. For the first six months of 2025, Total Operating Expenses reached $1,326,785, up from $1,171,642 in the first half of 2024. Research and development expense, which is part of the overall operating structure, was $107,868 in Q2 2025.

Here's a quick look at the key expense components for Q2 2025 versus the prior year:

Expense Category	Q2 2025 Amount (USD)	Q2 2024 Amount (USD)
Cost of Sales	1,340,854	1,561,090
Operating expenses	694,050	602,777
Research and development expense	107,868	111,660

Distribution and marketing costs: Supporting domestic and international distribution partners

United-Guardian, Inc. distributes products through a network of domestic and international partners. While specific line-item figures for distribution and marketing aren't broken out separately in the readily available summaries, these activities are embedded within the overall operating expenses. The company relies on its largest cosmetic distributor, Ashland Specialty Ingredients (ASI), though their reduced purchases impacted Q2 2025 sales.

Regulatory and compliance costs: Maintaining FDA approvals and ISO certification

The company leverages its in-house regulatory expertise to support product formulation, testing, and compliance with industry standards, including maintaining FDA approvals and ISO certification. These compliance efforts are a necessary, ongoing cost factored into the general operating structure, supporting the pharmaceutical and medical lubricant segments.

Dividend payments: A consistent strategy, with a Q1 2025 dividend of $0.35 per share

United-Guardian, Inc. maintains a consistent strategy of returning value to shareholders. The Board declared a cash dividend of $0.35 per share in Q1 2025, paid on February 18, 2025, marking the 30th consecutive year of dividend payments. Subsequently, a cash dividend of $0.25 per share was declared in July 2025, payable August 1, 2025. This results in an estimated total annual dividend for 2025 of $0.60 per share. The Q1 2025 dividend payment represented a net cash use of $1,607,893 in financing activities for that period.

The dividend history for the first half of 2025 looks like this:

• Q1 2025 Dividend: $0.35 per share.
• Q2/H1 2025 Dividend Declared: $0.25 per share.
• Total Estimated 2025 Annual Dividend: $0.60.

The Board balanced shareholder returns with retaining earnings for growth initiatives.

United-Guardian, Inc. (UG) - Canvas Business Model: Revenue Streams

You're looking at the core ways United-Guardian, Inc. (UG) brings in money as of late 2025. The revenue picture shows a clear reliance on the pharmaceutical side, even as the cosmetic ingredient business faces near-term headwinds.

The total top-line number for the first nine months of 2025 gives you the big picture:

• Total net sales for the nine-month period ended September 30, 2025, totaled $7,583,613.

Here's how the revenue streams broke down by percentage based on the second quarter of 2025 figures:

Revenue Stream	Q2 2025 Revenue Share
Pharmaceutical product sales	51.15%
Cosmetic ingredient sales	31.59%
Medical lubricant sales	17.26%

Drilling down into the performance trends for the first nine months of 2025 versus the prior year shows where the growth and the pressure points are:

• Pharmaceutical product sales: Generated 51.15% of Q2 2025 revenue, with sales for the first nine months of 2025 up 10% compared to the same period in 2024.
• Medical lubricant sales: Accounted for 17.26% of Q2 2025 revenue, and sales for the first nine months of 2025 were up 6% year-over-year.
• Cosmetic ingredient sales: Made up 31.59% of Q2 2025 revenue, but sales are down year-over-year, specifically experiencing a decrease in the third quarter compared with 2024. This was attributable primarily to reduced purchases by Ashland Specialty Ingredients ("ASI"), United-Guardian's largest marketing partner.

The final stream involves the finished goods business. This is where United-Guardian, Inc. directly markets its own consumer-facing products.

• Finished product/private label sales: This revenue comes from Guardian brand products marketed for esthetic markets, which includes providing private-label and contract manufacturing services to spas, salons, and dermatology clinics.

The company is definitely leaning on its pharmaceutical segment for stability right now. Finance: draft the 13-week cash flow view by Friday.